[go: up one dir, main page]

WO2002013845A3 - Inflammation associee au recepteur couple a la proteine g - Google Patents

Inflammation associee au recepteur couple a la proteine g Download PDF

Info

Publication number
WO2002013845A3
WO2002013845A3 PCT/EP2001/009466 EP0109466W WO0213845A3 WO 2002013845 A3 WO2002013845 A3 WO 2002013845A3 EP 0109466 W EP0109466 W EP 0109466W WO 0213845 A3 WO0213845 A3 WO 0213845A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
coupled receptor
protein coupled
inflammation related
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/009466
Other languages
English (en)
Other versions
WO2002013845A2 (fr
Inventor
Gabor Jarai
Shida Yousefi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Priority to JP2002518985A priority Critical patent/JP2004505648A/ja
Priority to EP01980246A priority patent/EP1364017A2/fr
Priority to AU2002212140A priority patent/AU2002212140A1/en
Publication of WO2002013845A2 publication Critical patent/WO2002013845A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002013845A3 publication Critical patent/WO2002013845A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant comme ingrédient actif: A) un polypeptide comprenant la séquence d'acide aminé de SEQ ID NO:2 ou SEQ ID NO:16 ou un variant fonctionnellement équivalent à ladite séquence d'acide aminé; ou B) un polynucléotide comprenant une séquence nucléotidique codant pour le polypeptide A); ou C) un anticorps immunoréactif avec le polypeptide A); ou D) un oligonucléotide antisens comprenant une séquence nucléotidique complémentaire de celle du polynucléotide B). L'invention concerne également l'utilisation de A), B), C) et D) dans des applications diagnostiques et thérapeutiques.
PCT/EP2001/009466 2000-08-18 2001-08-16 Inflammation associee au recepteur couple a la proteine g Ceased WO2002013845A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002518985A JP2004505648A (ja) 2000-08-18 2001-08-16 炎症関連ｇタンパク質共役受容体
EP01980246A EP1364017A2 (fr) 2000-08-18 2001-08-16 Inflammation associee au recepteur couple a la proteine g
AU2002212140A AU2002212140A1 (en) 2000-08-18 2001-08-16 Inflammation related g-protein coupled receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64165300A 2000-08-18 2000-08-18
US09/641,653 2000-08-18

Publications (2)

Publication Number Publication Date
WO2002013845A2 WO2002013845A2 (fr) 2002-02-21
WO2002013845A3 true WO2002013845A3 (fr) 2003-07-10

Family

ID=24573290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009466 Ceased WO2002013845A2 (fr) 2000-08-18 2001-08-16 Inflammation associee au recepteur couple a la proteine g

Country Status (4)

Country Link
EP (1) EP1364017A2 (fr)
JP (1) JP2004505648A (fr)
AU (1) AU2002212140A1 (fr)
WO (1) WO2002013845A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
EP1597587A2 (fr) * 2003-02-17 2005-11-23 Bayer HealthCare AG Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US20060078916A1 (en) * 2004-08-27 2006-04-13 Luc Aguilar HM74 and HM74a in cuboidal endothelial cells as associated with inflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056820A1 (fr) * 1997-06-12 1998-12-17 Smithkline Beecham Corporation Recepteur hm74a
WO2002018938A1 (fr) * 2000-09-01 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Procede d'identification de substances influençant de maniere positive des etats inflammatoires de maladies inflammatoires chroniques des voies aeriennes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056820A1 (fr) * 1997-06-12 1998-12-17 Smithkline Beecham Corporation Recepteur hm74a
WO2002018938A1 (fr) * 2000-09-01 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Procede d'identification de substances influençant de maniere positive des etats inflammatoires de maladies inflammatoires chroniques des voies aeriennes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EL OUAKFAOUI SOUAD ET AL: "Granulocyte-macrophage colony-stimulating factor modulates tapasin expression in human neutrophils.", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 65, no. 2, February 1999 (1999-02-01), pages 205 - 210, XP002230379, ISSN: 0741-5400 *
NOMURA H ET AL: "MOLECULAR CLONING OF CDNAS ENCODING A LD78 RECEPTOR AND PUTATIVE LEUKOCYTE CHEMOTACTIC PEPTIDE RECEPTORS", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 5, no. 10, October 1993 (1993-10-01), pages 1239 - 1249, XP002911511, ISSN: 0953-8178 *
PALS CORNELIEKE E G M ET AL: "Identification of cytokine-regulated genes in human leukocytes in vivo.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 105, no. 4, April 2000 (2000-04-01), pages 760 - 768, XP008013156, ISSN: 0091-6749 *
YOUSEFI SHIDA ET AL: "cDNA representational difference analysis of human neutrophils stimulated by GM-CSF", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 277, no. 2, 22 October 2000 (2000-10-22), pages 401 - 409, XP002179732, ISSN: 0006-291X *

Also Published As

Publication number Publication date
EP1364017A2 (fr) 2003-11-26
WO2002013845A2 (fr) 2002-02-21
AU2002212140A1 (en) 2002-02-25
JP2004505648A (ja) 2004-02-26

Similar Documents

Publication Publication Date Title
WO2001066597A3 (fr) Gene relatif a l'inflammation
WO2000025725A3 (fr) Antagonistes fonctionnels de l'activite hedgehog
WO1998055508A3 (fr) Proteines humaines ayant des domaines transmembranaires et adn codant ces proteines
EP2011510A3 (fr) Compositions pharmaceutiques comportant des fragments de protéine du virus de l'herpès simplex d'acitvité immunologique
WO2004043382A3 (fr) Variants ameliores de l'erythropoietine et methodes d'utilisation
WO2002022776A3 (fr) Variants du facteur vii de coagulation humaine
CA2529179A1 (fr) Vecteur viral aav recombine pour traitement de la maladie d'alzheimer
EP1719780A3 (fr) Polypeptide 10 du type cytokine de mammifère
WO1999006440A8 (fr) Nouveaux peptides synthetiques possedant des proprietes antimicrobiennes et de neutralisation d'endotoxines et permettant de lutter contre le syndrome de septicemie
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
EP1439231A3 (fr) Amino-terminale tronquée c-c chemokine et d'un antagoniste de chemokine
CA2287534A1 (fr) Microparticules biodegradables pour administration soutenue de medicaments therapeutiques
AU2002330289A1 (en) Preparation of a therapeutic composition
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
WO2002013845A3 (fr) Inflammation associee au recepteur couple a la proteine g
JP2003533188A5 (fr)
WO2001049711A3 (fr) Acides nucleiques codant pour des (poly)peptides ayant une activite de chips
JP2006505290A5 (fr)
WO2003097677A3 (fr) Nouvelles compostions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
CA2205564A1 (fr) Compositions pharmaceutiques comprenant des biopolymeres liberant de l'oxyde nitrique
CA2210871A1 (fr) Variantes de la dnase i humaine
WO2000068259A3 (fr) Composition vaccinale
NZ505350A (en) DNA encoding a tumour antigen peptide (43 kDa) for diagnosis or treatment of tumours
WO2002048182A3 (fr) Gene induit par un interferon-alpha
CA2397789A1 (fr) Nouvelle proteine kinase humaine et polynucleotides codant pour cette proteine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001980246

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002518985

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001980246

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001980246

Country of ref document: EP